ZLDPF
Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company markets lixisenatide under the brand names of Adlyxin and Lyxumia; Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia, congenital hyperinsulinism, and post bariatric surgery hypoglycemia; and Dasiglucagon dual-hormone artificial pancreas for automated diabetes management. The company's pipeline includes Dasiglucagon that is in Phase III clinical trials for congenital hyperinsulinism. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. Zealand Pharma A/S has collaboration agreements with Sanofi-Aventis Deutschland GmbH; Boehringer Ingelheim International GmbH; Alexion Pharmaceuticals, Inc.; and Beta Bionics, Inc. The company was incorporated in 1998 and is headquartered in Copenhagen, Denmark.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2026 Q1 | -5.58 | $34M | -$683M |
| 2025 Q4 | -5.34 | $69M | -$1.1B |
| 2025 Q3 | -0.90 | $50M | -$70M |
| 2025 Q2 | 107.08 | $9.1B | $8.5B |
| 2025 Q1 | -4.75 | $8M | -$510M |
| 2024 Q4 | -4.64 | $9M | -$183M |
| 2024 Q3 | -4.25 | $4M | -$296M |
| 2024 Q2 | -4.67 | $34M | -$237M |